These facts and background encouraged us to examine the anti-tumor effect of TAE226 in NSCLC, and we unexpectedly found that TAE226 preferably inhibits the proliferation of EGFR-mutant NSCLC cell lines including the T790M mutant, compared with EGFR-wild-type NSCLC cell lines. The gene discussed is EGFR; the disease is neoplasm.